U.S. Official Voices Concern About India Use Of Compulsory License
This article was originally published in PharmAsia News
Executive Summary
The U.S. Commerce secretary voiced concerns during a visit to India about the nation’s recent decision to invoke its new compulsory-licensing law to give Natco the right to market a generic of Bayer’s cancer drug Nexavar.